Prostate Cancer InfoResourcesJoin the FightResearch

Prostate Cancer Risk Increased in Obese Men
Long-term use of cholesterol-lowering statin drugs appears to raise the risk of prostate cancer among obese men

By Michelle Rizzo

Friday, August 22 (Reuters Health) - Use of cholesterol-lowering statin drugs, especially long-term use, appears to raise the risk of prostate cancer among obese men, according to findings of a new study.

"Given the epidemic of obesity in the U.S. and the frequent use of statins, the positive association we observed raises substantial concern as to the safety of these widely prescribed agents," Dr. Janet L. Stanford of the Fred Hutchinson Cancer Research Center in Seattle and colleagues wrote in the American Journal of Epidemiology.

In a population-based, case-control study, the researchers matched 1,001 men with prostate cancer diagnosed between 2002 and 2005 with 942 age-matched cancer-free controls from King County, Washington.

No overall association was observed between the risk of prostate cancer and the current or past use of statin treatment. Duration of statin use was also not associated with prostate cancer risk.

"We also found no evidence that use of a statin was associated with risk of developing more aggressive subtypes of prostate caner," Stanford said in an interview with Reuters Health. "Overall we found no support for the current hypothesis that statin use may reduce risk of prostate cancer."

However, the results do suggest a significant increase in the risk of developing prostate cancer associated with current statin use and with longer durations of use among obese men (defined as a body mass index of 30 greater).

"Among obese men," Stanford told Reuters Health, "current use of a statin was associated with a 50 percent increase in risk of prostate cancer; and use for 5 or more years was associated with an 80 percent increase in risk of the disease; both of these risk estimates were statistically significant."

These findings warrant further investigation, she said.

Reuters

Copyright © 2008 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

Would you like to receive prostate cancer news by email? Subscribe to NewsPulse